Synopsis Psoriasis, a chronic condition, is often managed with topical therapy. Recent data on a fixed combination of Halobetasol and Tazarotene (HP/TAZ) have been published. The present study aimed to review the efficacy and tolerability of the combination therapy. This week’s “ MED FACT ” discusses a clinical trial from Journal of Drugs in Dermatology, “Rapid Onset of Action in Patients with Moderate-to-Severe Plaque Psoriasis with Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination” Aug 2018.
Authors: Linda Stein Gold et.al. Key Takeaways Fixed HP/TAZ combination lotion provides quick relief from the symptoms of psoriasis, with benefits over individual ingredients. Objective: To review the efficacy and tolerability data with a specific focus on the first two weeks of therapy. Study Type: Multicenter, randomized, double-blind, vehicle-controlled…
